Cytek Biosciences Q2 revenue $30.4M (+59% YoY); operating income turns positive at $3.8M

Cytek Biosciences, Inc.

Revenue $30.4M, +59% YoY; gross margin improved to 65% from 43%.
Operating income $3.8M vs. ($0.2M) a year ago; net income $2.7M down from $8.1M.
Installed base reached 855 instruments, with 104 placements in Q2.
Launched Aurora Cell Sorter and Automated Sample Loader during the quarter.
Completed IPO in July 2021, raising $215M in net proceeds to strengthen balance sheet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.